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CORRESPONDENCE
Prospective Monitoring of BK Virus Load after
Discontinuing Sirolimus Treatment in a Renal
Transplant Patient with BK Virus Nephropathy
To the Editor—The polyomavirus BK may cause progressive
renal allograft failure in 1%–5% of kidney transplant recipients
[1, 2]. The risk factors for BK virus nephropathy (BKVN) are
not well understood but may involve rejection episodes and
treatment with antilymphocyte preparations and potent new
immunosuppressive drugs such as tacrolimus and mycopheno-
late mofetil [3]. Diagnosis of BKVN requires the immunohisto-
chemical demonstration of BK virus–infected tubular epithelial
cells in the allograft biopsy specimen. We note that detection of
BK virus DNA in plasma closely follows the course of BKVN
and may serve as a noninvasive tool for diagnosis and monitor-
ing [4]. Recently, Limaye et al. [5] confirmed our findings in a
retrospective study of 4 patients with BKVN and showed that
the BK virus load decreased when the immunosuppressive treat-
ment was reduced or when the renal allograft was removed.
We have independently established a quantitative assay of a
similar format (real-time fluorescent probe–based assay [Taq-
Man, Applied Biosystems]: primer 1, AGCAGGCAAGGGTT-
CTATTACTAAAT; primer 2, GAAGCAACAGCAGATTCT-
CAACA; probe, AAGACCCTAAAGACTTTCCCTCTGATC-
TACACCAGTTT labeled with 6-carboxyfluorescein at the 50
end and 6-carboxytetramethylrhodamine at the 30 end), which
allows the detection of BK virus over a linear range of 10–107
copies per reaction. We prospectively followed a 65-year-old
renal transplant recipient who developed BKVN in January
2001 while on an immunosuppressive treatment with cyclo-
sporine, prednisone, and sirolimus. The underlying diagnosis of
mesangioproliferative glomerulonephritis was made in 1987.
He began hemodialysis in 1999 and received a renal transplant
from a cadaver in October 2000. As shown in figure 1, initial
allograft function was good (creatinine clearance, 55 mL/min).
Two months after transplantation, a rise in serum creatinine
from 1.52 mg/dL (135 mmol/L) to 2.47 mg/dL (218 mmol/L)
was noted. Sirolimus concentrations (mean ^ SD) were 5:8 ^
2:4 ng/mL (median, 6.4 ng/mL; range, 3.0–6.6 ng/mL), and
blood levels of cyclosporine (mean ^ SD) were 242 ^ 108
ng/mL (median, 225 ng/mL; range, 122–324 ng/mL).
In the first allograft biopsy, a mononuclear and plasmacytoid
interstitial infiltration was seen together with an altered tubular
epithelium, and acute rejection was diagnosed. Intravenous
methylprednisolone (1000 mg for 3 days) was given, but renal
function did not improve. A second transplant biopsy 2 weeks
later revealed more-pronounced tubular alterations. BKVN was
diagnosed by immunohistochemistry. BK virus DNA was de-
tected in plasma, and the BK virus load was 3  106 copies/mL.
Sirolimus therapy was stopped; however, prednisone (15
mg/day) and cyclosporine therapy was continued (blood levels
[mean ^ SD], 156 ^ 26 ng/mL; median, 153 ng/mL; range,
76–121 ng/mL). Over the next 12 weeks, the BK virus load
decreased until it was no longer detectable (figure 1). In parallel,
allograft function improved, with a serum creatinine concen-
tration of 1.74 mg/dL (154 mmol/L).
We believe that this case is the first description of BKVN
while the patient was undergoing immunosuppressive triple
therapy with sirolimus. Of note, the sirolimus concentrations
had not been high nor had there been prior treatment with anti-
lymphocyte preparations. BKVN must be distinguished from
interstitial rejection, which may coexist at times [6]. In the
absence of rejection, treatment with steroids does not result in a
functional or histologic improvement [1, 2]. Because specific
antiviral treatment is not established, reduction of immunosup-
pression may be an option if carefully monitored [4]. In our
patient, sirolimus therapy was stopped while cyclosporine and
prednisone therapy was continued at slightly lower levels. Pro-
spective monitoring of the BK virus load revealed a decrease by
5 orders of magnitude over 12 weeks. This, together with the
improving allograft function, supported the critical decision to
reduce the immunosuppressive treatment.
The patient’s BK virus load was 3–4 orders of magnitude
higher than the levels determined by Limaye et al. [5]. This
difference in BK virus load cannot be attributed to sirolimus,
because we found similarly high BK virus loads in 9 patients
undergoing treatment with tacrolimus, a finding that we con-
firmed independently in 2 cases by limiting-dilution polymerase
chain reaction (PCR) [4]. In 2 of 41 control patients without
BKVN, we found BK virus loads of 511 and 748 copies/mL [4].
In fact, we have never observed histologically manifest BKVN
at BK virus levels of ,5000 copies/mL (authors’ unpublished
Figure 1. Time course (year-month-day) of serum creatinine con-
centration, immunosuppression, and BK virus load. Circles, serum
creatinine concentration; diamonds, BK virus load; +, allograft biopsy;
arrow, steroid pulse; boxes, duration of treatment with sirolimus,
cyclosporine, and prednisone.
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Reply
To the Editor—We appreciate the interest of Hirsch et al. [1] in
our recent study of quantitation of BK virus DNA in the blood of
patients with histologically documented BK virus nephropathy
(BKVN). In our study, we retrospectively analyzed serum
samples from 4 renal transplant patients with BKVN [2] and
showed that BK virus DNA appeared in blood weeks to months
before the histologic diagnosis of BKVN in renal biopsy speci-
mens. BK virus DNA was not detected in the blood of matched
control patients who did not develop histologic evidence of
BKVN. Furthermore, the levels of BK virus DNA in blood
decreased and/or became undetectable among patients who had
improvement in renal function or who underwent transplant
nephrectomy. We concluded that quantitation of BK virus
DNA in blood was useful for both the diagnosis and monitoring
of patients with BKVN.
Hirsch et al. [1] confirmed our findings by using a different
assay with a similar format (real-time, quantitative polymerase
chain reaction [PCR] with different target sequences) for a
patient with histologically documented BKVN [1]. The BK
virus DNA load in blood at the time of diagnosis of BKVN in
the patient was 3  106 copies/mL plasma and eventually
became undetectable over the next 12 weeks, as immunosup-
pression was reduced. Overall, the results from the two reports
are similar and provide evidence that BK virus DNA levels in
blood reflect the degree of renal involvement with BK virus.
These studies also suggest that monitoring BK virus load in
blood may be potentially useful both for identifying patients at
risk for developing BKVN and for monitoring response to
therapy (reduction in immunosuppression) among patients with
BKVN.
The finding that the absolute BK virus load in blood was sig-
nificantly different between the two assays is not surprising and
highlights the difficulties in interpreting results of PCR assays
between different laboratories, as documented for various other
viral pathogens. In our study, the BK virus load in the blood of
patients with BKVN ranged from 530 to 1:8  104 copies/mL,
which was significantly lower than the virus load of the patient
reported by Hirsch et al. [1]. In addition, Hirsch et al. report simi-
larly high levels in other patients with BKVN, although they did
not provide specific details. Although similar PCR methodolo-
gies (extraction and real-time quantitation) were used in the
two studies, different target sequences were used. Other factors
that could potentially explain the differences in the absolute BK
virus load in the two studies include differences in immunosup-
pression (specific agents and target levels), patient population
(mostly kidney/pancreas transplant recipients in our study vs.
kidney transplant recipients in the study by Hirsch et al.), extent
of BK virus nephropathy, and type of specimen used (serum vs.
plasma). Perhaps the most important difference between the
studies was the timing of blood samples relative to the diagnosis
of BKVN. In our study, the median timing of the blood samples
was 26.5 weeks (range, 5–69 weeks) before the histologic diag-
nosis of BKVN, whereas the majority of patients in the study by
Hirsch et al. appear to have had blood samples analyzed within
a few weeks of the histologic diagnosis of BKVN. It is possible
that the BK virus load increased several log-fold in the relatively
long duration between the timing of the blood samples and the
diagnosis of BKVN in our study. Given the retrospective nature
of our study, we are unable to test this hypothesis by analyzing
additional blood samples obtained closer to the histologic diag-
nosis of BKVN.
data). The reason for the difference in BK virus load levels is not
clear to us. The target sequences used in the respective real-time
PCR assays are not identical but overlap significantly in the gene
coding for the BK virus large T antigen. In both assays, sample
DNA is added to a master mix (5 mL of 25 mL in our assay vs.
10 mL of 50 mL in the assay used by Limaye et al. [5]). Both
groups use silica spin columns (Qiagen) for DNA preparation.
Elution of the DNA resulted in a 2-fold concentration in our pro-
cedure, compared with a 4-fold concentration in the assay used
by Limaye et al. [5]. Thus, inhibition of the real-time PCR
assay owing to a high DNA concentration does not seem likely.
Because of the implications of the absolute BK virus load for
diagnosis and for monitoring, the differences should be commu-
nicated and hopefully resolved.
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